MedPacto, Inc. (KOSDAQ:235980)
South Korea · Delayed Price · Currency is KRW 5,270.00
-220.00 (-4.01%)
Apr 29, 2026, 2:20 PM KST
MedPacto Revenue
In the year 2025, MedPacto had annual revenue of 3.90B KRW. MedPacto had revenue of 1.43B in the quarter ending December 31, 2025.
Revenue
3.90B
Revenue Growth
n/a
P/S Ratio
48.27
Revenue / Employee
n/a
Employees
n/a
Market Cap
188.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.90B | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EASY BIO,Inc. | 476.94B |
| Bioneer | 330.11B |
| Macrogen | 195.27B |
| JETEMA, | 76.90B |
| HLB Therapeutics | 69.56B |
| Amicogen | 41.98B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |